Shots:

• F-star to receive $17.5M up front and is eligible to receive ~$1.35B as near-term fees & milestones along with royalties on net sales of the product
• Janssen to get an exclusive royalty-bearing license globally to research- develop & commercialize up to 5 novels bispecific Abs directed to Janssen therapeutic targets using F-star’s Fcab and mAb2 platforms & will lead all research- development- and commercialization activities
• F-star's platform allows changes in the Fc region of a natural Ab to generate 2 additional distinct Ag binding sites. Fcab building blocks can be inserted into a natural IgG Ab to develop tetravalent mAb2 bispecific Abs that bind to two different Ag

 Ref: F-star | Image: Janssen